Samuel Wadsworth - Dimension Therapeutics Chief Scientific Officer
Executive
Dr. Samuel C. Wadsworth, Ph.D., is Chief Scientific Officer of the Company. Before joining Dimension, Dr. Samuel C. Wadsworth, Ph.D., has served as our chief scientific officer since November 2013. Before joining Dimension, Dr. Wadsworth served as the head of gene therapy research and early development at Sanofi Genzyme from 2011 to 2013. Previously, he served as group vice president for translational research at Genzyme from 1993 to 2010. He holds a Ph.D. from the University of Chicago and a B.A. from Southern Illinois University. since 2013.
| Age | 67 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 617 401-0011 |
| Web | www.dimensiontx.com |
Dimension Therapeutics Management Efficiency
Dimension Therapeutics' management efficiency ratios could be used to measure how well Dimension Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.78 M in liabilities with Debt to Equity (D/E) ratio of 16.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dimension Therapeutics has a current ratio of 3.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dimension Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Dimension Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dimension Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dimension to invest in growth at high rates of return. When we think about Dimension Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sheila Paine | Global Crossing Airlines | 61 | |
| J Jennex | Global Crossing Airlines | N/A | |
| Matthew CFA | HNI Corp | N/A | |
| Michael Roch | HNI Corp | 45 | |
| Jeff Walker | Global Crossing Airlines | N/A | |
| Michael Ferverda | Mesa Air Group | 80 | |
| Christopher McGinnis | Acco Brands | N/A | |
| Richard Nelson | Acco Brands | N/A | |
| Andrea Anzures | Volaris | N/A | |
| Kourtney Smith | HNI Corp | 54 | |
| Michael II | Mesa Air Group | N/A | |
| Jordi Porcel | Global Crossing Airlines | N/A | |
| Paul Daniel | Acco Brands | 58 | |
| Marcy Morita | Hawaiian Holdings | N/A | |
| Doug Cooper | Mesa Air Group | N/A | |
| Javier Suarez | Global Crossing Airlines | N/A | |
| Lara Wilson | Global Crossing Airlines | N/A | |
| Jaime Pous | Volaris | 44 | |
| Andres Pliego | Volaris | N/A | |
| Bradford Holt | Mesa Air Group | 64 | |
| Brent Overbeek | Hawaiian Holdings | 53 | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.0042 |
Dimension Therapeutics Leadership Team
Elected by the shareholders, the Dimension Therapeutics' board of directors comprises two types of representatives: Dimension Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dimension. The board's role is to monitor Dimension Therapeutics' management team and ensure that shareholders' interests are well served. Dimension Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dimension Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mary Thistle, Chief Business Officer | ||
| Michael Dybbs, Independent Director | ||
| Stephanie Haller, Vice President - Clinical Operations | ||
| George Migausky, Independent Director | ||
| Reed Clark, Sr. VP of Pharmaceutical Devel. | ||
| Ben Auspitz, Chairman of the Board, Co-Founder | ||
| Georges Gemayel, Independent Director | ||
| Alan Colowick, Independent Director | ||
| Rishi Gupta, Independent Chairperson of the Board | ||
| Sam Wadsworth, Chief Scientific Officer | ||
| Jean Franchi, CFO and Treasurer | ||
| Samuel Wadsworth, Chief Scientific Officer | ||
| MRCP MBBS, CEO and President and Director | ||
| Arlene Morris, Independent Director | ||
| Eric MD, Chief Medical Officer | ||
| Annalisa Jenkins, CEO, Director | ||
| John Hohneker, Director | ||
| Eric Crombez, Chief Medical Officer |
Dimension Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dimension Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.0042 | |||
| Profit Margin | (4.09) % | |||
| Operating Margin | (355.95) % | |||
| Current Valuation | 108.6 M | |||
| Shares Outstanding | 25.21 M | |||
| Shares Owned By Institutions | 71.22 % | |||
| Number Of Shares Shorted | 167.31 K | |||
| Price To Earning | (2.81) X | |||
| Price To Book | 4.13 X |
Pair Trading with Dimension Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dimension Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dimension Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Ralph Lauren could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ralph Lauren when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ralph Lauren - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ralph Lauren Corp to buy it.
The correlation of Ralph Lauren is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ralph Lauren moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ralph Lauren Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ralph Lauren can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Dimension Stock
If you are still planning to invest in Dimension Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dimension Therapeutics' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |